Valeant Pharmaceuticals (VRX) Apocalyptical Session; Nxt-ID (NXTD) Takes Upward Mobility


Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) sank more 55% to reach a new 52-week low during Tuesday’s trading session after the company issued downside guidance for 2016

The multinational specialty pharmaceutical company said that it now expects 2016 total revenue to be in the range of $11.0 billion to $11.2 billion and non-GAAP Adjusted EBITDA to be between $5.6 billion and $5.8 billion, versus the previously reported guidance ranges for the period of $12.5 billion to $12.7 billion for revenues and $6.9 billion to $7.1 billion for non-GAAP Adjusted EBITDA.

VRX stock is exchanging hands at $34.46, down $34.58 (ot -50.09%), and 117,504,523 of its sgares were traded so far

Valeant Pharmaceuticals International, which develops, manufactures, and markets pharmaceuticals, OTC products, and medical devices worldwide, has 341.19M Shares Outstanding and VRX stock one-year range is currently from $33.65 to $263.81 per share



The price of Nxt-ID, Inc. (Nasdaq:NXTD) stock soared over 34% to touch the $0.0.5796 mark in intraday trading Tuesday. The company said that its Wocket smart wallet will be seen in several commercials airing on Bloomberg TV, Fox Business News and CNBC, starting the week of March 21st.

NXTD stock is trading at $0.54, up $0.10 (or +24.13%), and 2,497,747 of its shares exchanged hands so far

Nxt-ID, a company focused on the growing m-commerce market, has 31.33M Shares Outstanding and NXTD stock 52-week range is from $0.16 to $4.20 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at